Anumana wins FDA clearance for ECG-AI algorithm

Screen shot of sample data from Anumana’s ECG-AI LEF. [Image courtesy of Anumana]Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.

Cambridge, Massachusetts-based Anumana, an Nference portfolio company, worked in collaboration with Mayo Clinic. They designed the breakthrough medical device to detect low ejection fraction (LEF) in patients at risk of heart failure. The company’s pulmonary hypertension (PH) early detection algorithm also won FDA breakthrough device designation last year.

Developed as software-as-a-medical device (SaMD), the algorithm screens LEF in adults at risk for heart failure. It uses data from a routine 12-lead electrocardiogram (ECG). Anumana developed it using research from Mayo Clinic that included more than 100,000 ECG and echocardiogram data pairs. The data came from more than 25 studies evaluating more than 40,000 patients in the U.S. and abroad.

Further data from 16,0…

Read more
  • 0

Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension

Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm.

Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in 2021, designed its AI-enhanced, electrocardiograph (ECG)-based PH early detection algorithm as a precise, non-invasive screening tool to provide earlier diagnosis for patients with PH that may otherwise go unnoticed until the disease has advanced.

The algorithm leverages 12-lead ECGs and is enabled by the nference platform that provides insight from more than 6 million de-identified patient records, including over 8 million ECGs. It analyzes the voltage-time data and within seconds provides a prediction of the likelihood of PH, reducing the time between initial symptoms and the first evaluation for PH via targeted cardiac imaging.

According to a news release, the algorithm was developed through a collaboration between data scie…

Read more
  • 0

Mayo Clinic helps launch two new companies for improved diagnostics

Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched.

Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release.

“The dramatically increased use of remote patient telemetry devices coupled with the rapidly accelerating development of AI and machine learning algorithms has the potential to revolutionize diagnostic medicine,” Mayo Clinic Platform president Dr. John Halamka said in the release. “With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings. The platform will also enable patients to take more control of their health and make better decisions based on insights delivered directly to them.”

Read more
  • 0